A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Bildiriler > Özet Bildiri · 2017
Yazarlar: Sibel GÖKSEL, AHMET GÜL, Cemil GÜRGÜN
ACR/ARHP Annual Meeting, Uluslararası, Poster, Özet Bildiri, 2017-2017